Larry D. Cripe

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Jonathan W. Friedberg, Jeff P. Sharman, John Sweetenham et al. · Blood · 2009 · 739 citations · Full text

Medicine, Oncology, Pharmacology +10

BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein

Ann Marie Pendergast, Lawrence A. Quilliam, Larry D. Cripe et al. · Cell · 1993 · 658 citations

Medicine, Cancer Biology, Molecular Biology +15

Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

Thomas E. Witzig, Ian W. Flinn, Leo I. Gordon et al. · Journal of Clinical Oncology · 2002 · 650 citations

Medicine, Hematology, Pharmacotherapy +14

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

Mark J. Levis, Farhad Ravandi, Eunice S. Wang et al. · Blood · 2011 · 399 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999

Larry D. Cripe, Hajime Uno, Elisabeth Paietta et al. · Blood · 2010 · 236 citations · Full text

Medicine, Oncology, Pharmacology +8